TELA Bio（NASDAQ:TELA）报告称，第四季度每股亏损$0.23，低于分析师预期的$0.22，低于预期4.55%。与去年同期每股亏损$0.53相比，这是亏损减少56.6%。公司报告的季度销售额为$1764.9万，低于分析师预期的$2316.6万，低于预期23.82%。相比去年同期的$1699.8万，销售额增长了3.83%。
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 56.6 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $17.649 million which missed the analyst consensus estimate of $23.166 million by 23.82 percent. This is a 3.83 percent increase over sales of $16.998 million the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.